14 Apr

Opportunities For Xtandi, Medivation’s Key Drug

WRITTEN BY Jillian Dabney

Xtandi, Medivation’s key drug

Enzalutamide, known by its brand name Xtandi, is an androgen receptor inhibitor. It is the only commercialized product in Medivation’s (MDVN) portfolio.

In August 2012, Medivation and partner Astellas Pharma received approval from the FDA for treating metastatic castration-resistant prostate cancer (or mCRPC) patients who have previously received docetaxel. In September 2014, both partners received FDA approval for treating mCRPC patients who have not received docetaxel chemotherapy.

Opportunities For Xtandi, Medivation’s Key Drug

Label expansions for Xtandi

Currently, Xtandi is approved for use in prostate cancer patients who have received chemotherapy, as well as those who haven’t. In this particular space, the drug directly competes with Johnson & Johnson’s (JNJ) Zytiga.

Xtandi offers a progression-free survival (or PFS) benefit over AstraZeneca’s (AZN) Casodex. According to the National Cancer Institute, “The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works.” Another phase 3 trial is being run as a challenge to Abbvie’s (ABBV) Lupron.

Xtandi possesses a considerable untapped opportunity in the form of upstream prostate cancer indications. Medivation is expanding the drug beyond prostate cancer treatment, and it plans to conduct a phase 3 trial for triple negative breast cancer (or TNBC) that would start in the second half of 2016. The company is conducting investigational studies for upstream prostate cancer as well as hepatocellular carcinoma.

In March 2016, Medivation and its partner, Astellas Pharma, noted that it initiated “ARCHES Phase III registrational trial, which will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (or ADT) versus placebo with ADT in metastatic hormone-sensitive prostate cancer (or mHSPC) patients.”

For diversified exposure to this industry, investors can choose to invest in the SPDR S&P Biotech ETF (XBI), which holds 2.1% of its total portfolio in Medivation.

In the next part of this series, we’ll look at Xtandi in greater detail.

Latest articles

German chip maker Infineon Technologies has reportedly raised 1.55 billion euros (~$1.74 billion) in capital by selling its shares to fund its acquisition of Cypress Semiconductor (CY). Infineon has sold ~113 million new shares at 13.70 euros each.

As of June 18, Dunkin’ Brands (DNKN) was trading at $80.07, an 8.9% rise since reporting its first-quarter earnings on May 2. Also, DNKN was trading at a premium of 29.8% from its 52-week low of $61.69 and a discount of 1.6% from its 52-week high of $81.40.

19 Jun

Are Lower Oil Prices Weighing on ExxonMobil Stock?

WRITTEN BY Maitali Ramkumar

ExxonMobil (XOM) stock has fallen 7.1% in the second quarter so far. Let's review ExxonMobil's stock performance in comparison to oil price changes and equity market movements in the quarter.

19 Jun

As Facebook Unveils Libra, MSFT and CRM Join a Blockchain Group

WRITTEN BY Mayur Sontakke, CFA, FRM

On June 18, Facebook (FB) launched Libra, its own cryptocurrency. On the same day, CoinDesk published another piece of blockchain news that didn’t receive as much fanfare as Facebook’s Libra news. Was the timing a coincidence? We think not.

Uber Technologies (UBER) has picked Melbourne as another test site for its flying taxi service known as UberAir. The Australian city is the first international test site Uber has chosen for its flying taxi service. The addition of Melbourne brings the number of test locations Uber has picked for its UberAir service to three.

Lyft (LYFT) and Uber Technologies (UBER) are pushing back against California legislation that would require them to recognize their drivers as employees rather than independent contractors. The legislation would require companies like Lyft to give their drivers the compensation and benefits spelled out under California’s employment regulations.

172.31.38.64